Livedoid vasculitis
Livedoid vasculitis bụ ọrịa akpụkpọ anụ na-adịghị ala ala nke a na-ahụkarị na ụmụ nwanyị na-eto eto ruo n'etiti. Otu okwu mkpọ okwu eji kọwaa njirimara ya bụ "ọnya purpuric na-egbu mgbu nke nwere ụkpụrụ reticular nke nsọtụ ala" (PURPLE). Ejikọtara ya na ọtụtụ ọrịa, gụnyere ọbara mgbali elu na-adịghị ala ala na varicosities.
☆ Na nsonaazụ Stiftung Warentest nke 2022 sitere na Germany, afọ ojuju ndị ahịa na ModelDerm dị ntakịrị ntakịrị karịa na nyocha telemedicine akwụ ụgwọ.
Enwere ike iso ya na mgbu.
References
Livedoid vasculopathy bụ ọrịa akpụkpọ ahụ na-adịghị ahụkebe nke ọnya na-egbu mgbu nke na-alọghachi azụ n'ụkwụ ala.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy bụ ọrịa akpụkpọ ahụ na-adịghị ahụkebe nke na-ebute ọnya ọnya na-apụta ugboro ugboro n'ụkwụ ala, na-ahapụkwa ọnya icha mmiri nke a maara dị ka atrophie blanche. Ọ bụ ezie na a ka amabeghị kpọmkwem ihe kpatara ya, a kwenyere na mmụba ọbara na-agbakọta (hypercoagulability) bụ isi ihe na-akpata, na nsị na-arụ ọrụ nke abụọ. Ihe na-enye aka na clotting gụnyere dị ka ndị a - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. Na biopsies, ọnọdụ ahụ na-egosi mkpụkọ ọbara n'ime arịa, itosi mgbidi arịa, na ọnya. Ọgwụgwọ na-agụnye usoro dị iche iche na-elekwasị anya na igbochi mkpụkọ ọbara na ọgwụ dịka ọgwụ mgbochi platelet, ndị na-edozi ọbara, na ọgwụgwọ fibrinolytic. Enwere ike iji ọgwụ dị iche iche mee ihe maka ọnọdụ akpụkpọ ahụ - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy bụ ọnọdụ na-adịghị ahụkebe ebe ọnya na-apụta na ụkwụ abụọ. A na-eche na ọ bụ ihe kpatara mkpụkọ ọbara n'obere arịa ọbara bụ n'ihi mmụba nke mkpụkọ na mbelata mkpụkọ, yana mmebi nke eriri arịa ahụ. Ọ na-adịkarị n'ebe ụmụ nwanyị nọ, karịsịa n'agbata afọ 15 na 50. Ịkwụsị ịṅụ sịga, ilekọta ọnyá, na iji ọgwụ ndị dị ka ndị na-edozi ọbara na ọgwụ antiplatelet dị irè.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
